<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2459">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04363450</url>
  </required_header>
  <id_info>
    <org_study_id>LSU NO HSC IRB 20-050</org_study_id>
    <nct_id>NCT04363450</nct_id>
  </id_info>
  <brief_title>Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP)</brief_title>
  <acronym>HCQPreP</acronym>
  <official_title>Hydroxychloroquine as Primary Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Louisiana State University Health Sciences Center in New Orleans</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lafayette General Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Louisiana at Lafayette</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Louisiana State University Health Sciences Center in New Orleans</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This a double-blind, randomized, placebo-controlled clinical trial to determine if primary
      prophylaxis with hydroxychloroquine in healthcare workers reduces symptomatic COVID-19
      infection. Healthcare workers will be randomized at a 1:1 allocation between intervention and
      placebo arms and followed for 12 weeks. This study will enroll up to 1,700 participates in
      Lafayette, Louisiana. The primary outcome will number of symptomatic COVID-19 infections.
      Secondary endpoints included number of days healthcare workers are absent from work and rate
      of severe infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a double blind placebo controlled at two hospitals in Lafayette, Louisiana
      aiming to enroll 1700 participants with a 1:1 randomization. The HCQ dose in 400mg twice on
      day 1, then 200mg twice weekly. The primary outcome variable is development of symptomatic
      COVID-19 infection. The secondary objectives are number of days absent from work due to
      symptomatic COVID-19 infection and rate of severe disease due to COVID-19 (hypoxia in setting
      of &gt;50% lung involvement on chest imaging, respiratory failure, shock or end-organ damage).
      The study will enroll participants for four weeks with and plan to treat with
      hydroxychloroquine versus placebo for a total of 12 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 27, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, placebo-controlled, double-blind study with 1:1 randomization of hydroxychloroquine to placebo</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Participants will be randomized to the investigational drug (hydroxychloroquine) or placebo. Both will have identical appearance and will be taken at the same dosing interval. The administration of the drug and assessment will be blinded. After final analysis, study arms will be unmasked.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of symptomatic COVID-19 infection in healthcare workers</measure>
    <time_frame>12 weeks</time_frame>
    <description>Number of participants who develop symptoms of COVID-19 in the setting of a positive COVID-19 assay</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absenteeism from work due to COVID-19</measure>
    <time_frame>12 weeks</time_frame>
    <description>Number of days healthcare workers are absent from work due to symptomatic COVID-19 infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of COVID-19 infection</measure>
    <time_frame>12 weeks</time_frame>
    <description>Rate of severe COVID-19 infection in healthcare works (hypoxia in setting of chest imaging &gt;50% lung involvement, respiratory failure, end organ damage or shock)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1700</enrollment>
  <condition>COVID-19</condition>
  <condition>Corona Virus Infection</condition>
  <condition>Wuhan Coronavirus</condition>
  <condition>Prophylaxis</condition>
  <condition>Healthcare Worker</condition>
  <condition>Sars-CoV2</condition>
  <condition>Hydroxychloroquine</condition>
  <arm_group>
    <arm_group_label>Hydroxychloroquine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydroxychloroquine loading dose will be given as 400mg for two doses 12 hours apart. This will then be followed by maintenance dosing of 200mg twice weekly for the remainder of the trial.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>An identical placebo will be administered on an identical dosing interval and frequency.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>Hydroxychloroquine loading 400mg (2 capsules) twice 12 hours apart followed by 200mg (1 capsule) twice weekly</description>
    <arm_group_label>Hydroxychloroquine</arm_group_label>
    <other_name>HCQ PreP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Loading dose of two placebo capsules twice 12 hours apart followed by 1 capsule twice weekly</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age â‰¥ 18 years

          2. Healthcare or Hospital Worker who has direct patient contact

          3. Willing to participate in the research.

          4. Able to understand and sign the informed consent form

        Exclusion Criteria:

          1. Age &lt; 18 years

          2. History of ventricular arrhythmia or use of Class IA, IC and III anti-arrhythmics

          3. Known prolonged QTc interval

          4. History of retinal disease

          5. Kidney failure with GFR &lt;10%

          6. Chronic hepatic disease w/ Child-Pugh class B or C

          7. Hypersensitivity to chloroquine or hydroxychloroquine

          8. Currently taking chloroquine or hydroxychloroquine

          9. Unwilling to participate

         10. Unable to understand and/or sign the informed consent form.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ann D. Chauffe, DO, MPH</last_name>
    <phone>337-261-6161</phone>
    <email>achauf@lsuhsc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rebecca B. Lee, DO, MS</last_name>
    <phone>337-261-6000</phone>
    <email>rlee10@lsuhsc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lafayette General Medical Center</name>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <zip>70503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann D Chauffe, DO, MPH</last_name>
      <phone>337-261-6000</phone>
      <email>achauf@lsuhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Rebecca B Lee, DO, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicholas Sells, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>James B Falterman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carl Sabottke, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Stouts, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ann D Chauffe, DO, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital and Clinics</name>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <zip>70506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann D Chauffe, DO, MPH</last_name>
      <phone>337-261-6000</phone>
      <email>achauf@lsuhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Ann D Chauffe, DO, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rebecca B Lee, DO, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicholas Sells, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>James B Falterman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carl Sabottke, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Stout, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>April 23, 2020</study_first_submitted>
  <study_first_submitted_qc>April 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2020</study_first_posted>
  <last_update_submitted>August 31, 2020</last_update_submitted>
  <last_update_submitted_qc>August 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Louisiana State University Health Sciences Center in New Orleans</investigator_affiliation>
    <investigator_full_name>Ann Chauffe</investigator_full_name>
    <investigator_title>DO, MPH</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>COVID-19 Prophylaxis</keyword>
  <keyword>Healthcare Workers</keyword>
  <keyword>SARS-COV-2</keyword>
  <keyword>Hydroxychloroquine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

